Kynurenic acid

Catalog No.S4719 Synonyms: Quinurenic acid, Kynurenate

For research use only.

Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.

Kynurenic acid Chemical Structure

CAS No. 492-27-3

Selleck's Kynurenic acid has been cited by 1 Publication

Purity & Quality Control

Choose Selective NMDAR Inhibitors

Biological Activity

Description Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.
Targets
α7 nicotinic acetylcholine receptor [1] glutamate receptors [2] NMDAR [4]
In vitro

Kynurenic acid(KYNA) is neuroactive tryptophan metabolites formed along the kynurenine pathway. It is considered a non-competitive antagonist of glutamate receptors of NMDA type. KYNA, at low concentration, inhibits FGF-1 release in all cellular models and displays a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro[2].

In vivo Treatment with KYNA (30–100 mg per kg of body weight, intravenously) 4 h before the start of heat stress significantly (P<0.05) and dose-dependently decreases the survival time to new values of 152–356 min compared with normothermic rats. KYNA protects against hypotension but not hyperthermia during heatstroke. KYNA attenuates hypothalamic neuronal degeneration and apoptosis during heatstroke. Also spleen, kidney, liver, and lung apoptosis during heatstroke are decrease. KYNA up-regulates serum IL-10 levels but down-regulates serum TNF-α and ICAM-1 levels. KYNA treatment significantly prevents the occurrence of heat-induced multi-organ damage and inflammation without affecting the induced hyperthermia. Only high doses of KYNA proved to be neuroprotective in neonatal rats by reducing anoxia or hypoxia-ischemia-induced brain edema and in adult rats and gerbils given before ischemia induction. KYNA cannot cross the blood-brain barrier[3].

Protocol (from reference)

Animal Research:

[3]

  • Animal Models: Adult male Sprague-Dawley rats
  • Dosages: 30-100 mg/kg
  • Administration: i.v

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 189.17
Formula

C10H7NO3

CAS No. 492-27-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05280054 Recruiting Drug: AV-101|Drug: Probenecid Drug Drug Interaction VistaGen Therapeutics Inc.|Parexel December 23 2021 Phase 1
NCT04013555 Recruiting Drug: N-acetylcysteine (NAC)|Drug: Placebo|Drug: Tryptophan Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder University of Maryland Baltimore January 20 2020 Phase 1|Phase 2
NCT03901859 Unknown status -- Attention Deficit Hyperactivity Disorder National Taiwan University Hospital April 1 2019 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Kynurenic acid | Kynurenic acid supplier | purchase Kynurenic acid | Kynurenic acid cost | Kynurenic acid manufacturer | order Kynurenic acid | Kynurenic acid distributor